The Epilepsy Foundation’s purpose in working with the pharmaceutical industry

The Epilepsy Foundation’s mission is to lead the fight to overcome the challenges of living with epilepsy and to accelerate therapies to stop seizures, find cures and save lives. We work with all ethical companies, organizations and individuals that share our mission and can help advance us toward that goal. Included among these are pharmaceutical, biotechnology and medical device companies, as they play a pivotal role in manufacturing current U.S. Food and Drug Administration (FDA)-approved treatments and developing the next generation of epilepsy treatments. We therefore work with the pharmaceutical, biotechnology and medical device industries to:

  • Speed promising research findings towards development of new treatments
  • Bring attention to the specific issues and needs of people affected by epilepsy
  • Provide scientific and clinical expertise to ensure the development, availability and appropriate use of FDA-approved therapies and devices
  • Leverage and deploy resources to improve the quality of life for all people affected by epilepsy and increase public understanding of what it means to live with epilepsy

The Epilepsy Foundation keeps people impacted by epilepsy at the center of everything we do. This means we:

  • Earn and maintain the trust of people impacted by epilepsy by always acting with the utmost integrity
  • Give strong voice to the hopes and concerns of people impacted by epilepsy, including the issues of cost, access, efficacy and safety of existing and new treatments to drive positive change
  • Are transparent as to the purpose and nature of our relationships, including disclosure of any financial support received and its purpose
  • Maintain independence and vigilantly safeguard against any potential for undue influence by the pharmaceutical industry or its agents

2020 (July 1, 2019-June 30, 2020) Pharmaceutical Contributions

  • Total pharmaceutical revenue including paid advertising: $2.6 million
  • Percentage of total Epilepsy Foundation revenue: 15% of overall funding
  • Pharmaceutical sponsorship and educational grant support: $2.6 million 
    • Total sponsorship and educational grant support by companies without an epilepsy therapy or product on market: $361,000
    • Total sponsorship and educational grant support by companies with an epilepsy product on market in 2018: $2.97 million

Companies Giving More Than $5,000

  • Greenwich Biosciences: $695,760.00 
  • Eisai Inc.: $336,500.00 
  • UCB Pharma Inc.: $300,000.00
  • Sunovion Pharmaceuticals Inc.: $159,580.00 
  • SK Life Sciences: $155,000.00
  • Neurelis: $150,000.00
  • LivaNova: $110,000.00
  • Pfizer Inc.: $50,000.00 
  • Zogenix: $50,000.00 
  • Aquestive: $50,000.00 
  • Otsuka Pharmaceuticals: $50,000.00 
  • Xenon Pharmaceuticals: $40,000.00 
  • Supernus Pharmaceuticals, Inc.: $30,000.00 
  • Medtronic Corporation: $29,500.00 
  • Marinus Pharmaceuticals, Inc.: $26,000.00 
  • Anavex Life Sciences: $25,000.00 
  • Ovid Therapeutics: $25,000.00 
  • SAGE Therapeutics: $25,000.00
  • Celgene: $25,000.00 
  • Takeda: $25,000.00 
  • Cerevel Therapeutics: $25,000.00 
  • Encoded Therapeutics, Inc.: $25,000.00 
  • Neurocrine Biosciences, Inc.: $25,000.00 
  • Zynerba Pharmaceuticals, Inc.: $25,000.00 
  • Engage Therapeutics: $10,000.00 
  • Biogen: $10,000.00 
  • NeuroPace, Inc.: $5,625.00 
  • Ultragenyx Pharmaceutical Inc.: $5,000.00 
  • Monteris Medical: $5,000.00 
Authored By: 
Jeanette Stoltzfus MSW
Authored Date: